SUBSCRIBE
SUBSCRIBE
Greg Slabodkin

Greg Slabodkin

Greg is a seasoned editor/writer who has covered the healthcare, life sciences and medical device industries for several tech trade publications. He is the recipient of a Post-Newsweek Business Information Editorial Excellence Award for his news reporting and a Gold Award for Best Case Study from the American Society of Healthcare Publication Editors. In addition, Greg is a Healthcare Fellow from the Society for Advancing Business Editing and Writing. He is an avid Buffalo Bills football fan, likes to kayak and plays guitar.

Tim Hunt, CEO of the Alliance for Regenerative Medicine, provides welcome remarks at 2024 Cell & Gene Meeting on the Mesa.
Cell and gene therapy
Cell and Gene Therapy Investment Ticks Up After Hard Few Years
Tim Hunt, CEO of the Alliance for Regenerative Medicine, said Monday at the 2024 Cell & Gene Meeting on the Mesa that investments reached $10.9 billion in the first half of this year—outpacing 2019’s $9.8 billion total—but far below the pandemic peak.
October 8, 2024
 · 
4 min read
 · 
Greg Slabodkin
Central Coast New South Wales Australia – May 21, 2024 Assortment of weight loss and diabetic drugs on the table
Editorial
Obesity Drug Shortage Ends for Lilly, Continues for Novo as Industry Bolsters Manufacturing
Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the insatiable demand for weight loss drugs.
October 4, 2024
 · 
3 min read
 · 
Greg Slabodkin
Phoenix, Arizona/
Business
Meeting on the Mesa to Highlight Cell and Gene Therapy Opportunities, Challenges
Stephen Majors from the Alliance for Regenerative Medicine, which hosts the conference, spoke with BioSpace about what the more than 2,000 attendees can expect to learn next week in Phoenix about the pressing issues confronting the industry.
October 3, 2024
 · 
7 min read
 · 
Greg Slabodkin
Podcast
BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day
Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; new IVF and abortion laws could derail women’s health research; Roche touts CDK inhibitor deal and obesity pipeline and BioSpace heads to Meeting on the Mesa.
October 2, 2024
 · 
1 min read
 · 
Heather McKenzie
Editorial
Lilly Is Not ‘Feeling the Bern’ on Drug Prices Like Novo: Why the Double Standard?
Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s rival drugs, is not fair.
September 27, 2024
 · 
3 min read
 · 
Greg Slabodkin
External view of the U.S. Capitol building
Business
Novo CEO Reluctantly Agrees to Meet With PBMs on Ozempic, Wegovy Prices
In a Tuesday Senate hearing on Novo Nordisk’s drug pricing, CEO Lars Fruergaard Jørgensen said he would be willing to sit down with the three largest pharmacy benefit managers who committed that they would expand coverage of Ozempic and Wegovy if Novo lowers its list prices for the blockbuster drugs.
September 25, 2024
 · 
3 min read
 · 
Greg Slabodkin
IRA
Cancer and Diabetes Drugs Expected to Dominate 2025 Medicare Negotiations Under IRA
Many Big Pharma companies including Pfizer, Merck and BMS make the drugs that some researchers expect to be selected by CMS for next year’s Medicare price negotiations alongside analysts’ top pick, Novo Nordisk’s Ozempic.
September 25, 2024
 · 
2 min read
 · 
Greg Slabodkin
Podcast
Novo Grilled by Senate, PhRMA’s IRA Win and BMS’ KarXT Awaits Approval
New revelations from the showdown between Novo Nordisk’s CEO and Bernie Sanders’ Senate health committee Tuesday; PhRMA’s legal victory in IRA case; the federal interest rate cut and anticipated approval for schizophrenia.
September 25, 2024
 · 
1 min read
 · 
Heather McKenzie
Novo Nordisk's logo on the facade of its building in Germany
Policy
Novo’s Ozempic Seen as Shoo-In for Next Round of Medicare Price Negotiations
Novo Nordisk’s blockbuster type 2 diabetes medication is a sure bet for the list of the next 15 drugs whose Medicare prices will be negotiated in 2025 and go into effect in 2027, according to analysts and academics.
September 25, 2024
 · 
3 min read
 · 
Greg Slabodkin
United States Capitol Building & dollar bills /
Policy
Novo CEO, Sanders to Face Off Over US Prices for Ozempic and Wegovy
In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard Jørgensen will be asked to defend the drugs’ U.S. monthly list prices of $969 and $1,349, respectively.
September 24, 2024
 · 
3 min read
 · 
Greg Slabodkin
Tumor microenvironment concept with cancer cells, T-Cells, nanoparticles, cancer associated fibroblast layer of tumor microenvironment normal cells, molecules, and blood vessels 3d rendering
Cancer
ADCs, Bispecifics and Radiopharma Take Center Stage at ESMO24
The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer treatment—antibody-drug conjugates, bispecifics and radiopharmaceuticals—while anti-TIGIT therapies made a bit of a comeback.
September 20, 2024
 · 
3 min read
 · 
Greg Slabodkin
Podcast
Sickle Cell Gene Therapies Reach Patients, Moderna Cuts, Obesity Pill Race and ESMO 2024
Infusions of Vertex and CRISPR Therapeutics’ Casgevy and bluebird bio’s Lyfgenia have begun; Moderna targets 10 approvals through 2027; more oral obesity drug data; the latest from ESMO and more.
September 18, 2024
 · 
1 min read
 · 
Heather McKenzie
Dragon and eagle with money
Editorial
BIOSECURE Act Targets China but Fails to Address Fallout for US Biopharma
It’s time for Congress to step up and fund America’s supply chain independence from Chinese companies by bolstering our domestic manufacturing capabilities.
September 13, 2024
 · 
4 min read
 · 
Greg Slabodkin
Podcast
BioMarin Fails to Reassure Investors, Terns Moves Forward in Obesity, ESMO Excitement
BioMarin’s new business strategy leaves investors with questions; Lykos CEO steps down; Terns releases compelling data on oral weight loss candidate; and more.
September 11, 2024
 · 
1 min read
 · 
Heather McKenzie
Neuron colorful watercolor vector illustration
Editorial
Roche and Sanofi MS Trials Show Potential, Challenges of Oral BTK Inhibitors
Roche’s fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi’s tolebrutinib met the primary endpoint in a Phase III trial for progressive MS but flopped in two late-stage relapsing MS studies.
September 6, 2024
 · 
3 min read
 · 
Greg Slabodkin
Load More